ropinirole

(redirected from Requip XL)
Also found in: Dictionary.

ropinirole

 [ro-pin´ĭ-rōl″]
a dopamine agonist used as the hydrochloride salt in treatment of Parkinson's disease; administered orally.

ropinirole

/ro·pin·i·role/ (ro-pin´ĭ-rōl″) a dopamine agonist used as the hydrochloride salt as an antidyskinetic in the treatment of Parkinson's disease.

ropinirole

(rō-pĭn′ə-rōl′)
n.
A dopamine agonist, C16H24N2O, used in its hydrochloride form to treat Parkinson's disease and restless legs syndrome.

ropinirole

an antiparkinsonian agent.
indication It is used to treat parkinsonism.
contraindication Known hypersensitivity to this drug prohibits its use.
adverse effects Life-threatening effects are hemolytic anemia, leukopenia, and agranulocytosis. Other adverse effects include psychosis, hallucination, dystonia, depression, dizziness, constipation, dyspepsia, flatulence, rash, sweating, tachycardia, hypertension, hypotension, syncope, palpitations, blurred vision, impotence, urinary frequency, pharyngitis, rhinitis, sinusitis, bronchitis, and dyspnea. Common side effects include agitation, insomnia, nausea, vomiting, anorexia, dry mouth, and orthostatic hypotension.

ropinirole

A drug with dopamine-like action used to treat PARKINSON'S DISEASE. A brand name is Requip.
References in periodicals archive ?
Requip XL is the first and only "once daily" drug for Parkinson's sufferers which significantly reduces patients "off time".
Actavis believes that this is the first generic Requip XL available in the United States.
GlaxoSmithKline's Requip XL, for example, showed relatively constant first-line therapy use among newly diagnosed patients and Boehringer Ingelheim's Mirapex ER has seen its patient share increase among the same patient population.
How did the launch of generics impact the reimbursement of GlaxoSmithKline's Requip XL (ropinirole) and Boehringer Ingelheim's Mirapex (pramipexole), and how will it affect the reimbursement of the extended-release formulations of these branded drugs?
Previously, XenoPort was entitled to detail Requip XL commencing upon its exercise of the co-promotion option and ending upon the launch of Solzira.
As originally constructed, the GSK collaboration agreement gave XenoPort the right to detail Requip XL for a relatively short period of time prior to the launch of Solzira," said Vincent J.
GlaxoSmithKlines Requip XL (ropinirole extended-release) is set to become the market leading dopamine agonist in 2009.